Swiss pharma firm Lonza expands partnership with US client

Lonza is expanding its collaboration with an American biopharmaceutical company, the identity of which has not been disclosed. The Basel-based pharmaceutical contract manufacturer is set to commence production for two new biologics programmes, with an option for two further programmes. The services will be provided from Lonza’s US and European sites, offering geographical flexibility and security of supply, according to the Basel-based group. The expanded collaboration includes long-term commitments across a broad portfolio of multiple biological programmes. This evolving portfolio of innovative programmes supports demand flexibility and development risk management, with the potential to gradually increase capacity, including the transition to commercial production. The cumulative value of the contracts could reach several billion francs. In recent years, Lonza has gradually expanded its relationship with this client. Development and manufacturing services under this strategic ... Full story here Are you the author? Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: Featured,newsletter